Korro Bio, Inc. (NASDAQ:KRRO) CFO Sells $56,000.00 in Stock

Korro Bio, Inc. (NASDAQ:KRRO) CFO Vineet Agarwal sold 800 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $70.00, for a total transaction of $56,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Vineet Agarwal also recently made the following trade(s):

• On Thursday, October 17th, Vineet Agarwal sold 10,216 shares of Korro Bio stock. The shares were sold at an average price of $78.26, for a total value of $799,504.16.

Korro Bio Stock Down 11.4 %

NASDAQ:KRRO traded down $8.36 during trading hours on Tuesday, reaching $65.14. 168,078 shares of the company traded hands, compared to its average volume of 68,486. Korro Bio, Inc. has a 1 year low of $30.00 and a 1 year high of $98.00. The business’s 50-day moving average price is $49.10 and its two-hundred day moving average price is $46.85.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($2.43) EPS for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.04). On average, research analysts anticipate that Korro Bio, Inc. will post -10.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KRRO has been the topic of a number of recent analyst reports. Royal Bank of Canada raised their price target on shares of Korro Bio from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Monday, October 21st. HC Wainwright raised their price target on Korro Bio from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. William Blair began coverage on Korro Bio in a research note on Wednesday, August 14th. They set an “outperform” rating and a $180.00 target price on the stock. Finally, Raymond James began coverage on shares of Korro Bio in a research note on Monday, October 21st. They set a “strong-buy” rating and a $153.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $142.17.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KRRO. Bank of New York Mellon Corp bought a new stake in Korro Bio during the second quarter worth approximately $649,000. Rhumbline Advisers bought a new position in shares of Korro Bio in the second quarter worth about $279,000. Atlas Venture Life Science Advisors LLC lifted its position in Korro Bio by 1.6% in the second quarter. Atlas Venture Life Science Advisors LLC now owns 1,137,149 shares of the company’s stock worth $38,515,000 after purchasing an additional 17,857 shares during the period. Brown Brothers Harriman & Co. bought a new stake in shares of Korro Bio in the 2nd quarter worth about $28,000. Finally, Tri Locum Partners LP bought a new stake in shares of Korro Bio during the second quarter valued at approximately $2,419,000. 13.18% of the stock is owned by institutional investors and hedge funds.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).